Latest Breaking News On - ஜேனட் சுத்தி - Page 1 : comparemela.com

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19 BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients in the United Kingdom (UK), Ireland and other countries. AT-527 is an orally administered, direct-acting developmental antiviral agent derived from Atea’s purine nucleotide prodrug platform.

United statesUnited kingdomJean pierre sommadossiCarol guacceroJanet hammondJonae barnesAtea pharmaceuticalsCorporate communicationsAtea pharmaceuticals incChief executive officerChief development officerInvestor relationsஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்ஜேனட் சுத்திபெருநிறுவன தகவல்தொடர்புகள்